AURKA inhibition is attractive in cholangiocarcinoma as it has been shown to interact with and control a variety of proteins that play key roles in cholangiocarcinoma pathogenesis such as STAT3 36 and Mcl-122. Here, STAT3 is linked to cholangiocarcinoma.